The Efficacy of Topical Interferon Alpha 2b Treatment in Refractory Vernal Keratoconjunctivitis

Vural, Ece Turan; Acar, Banu Torun; Acar, Suphi

doi:10.3109/09273948.2012.656877

Cited by 12 publications

(20 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although most positive impacts were seen within two months of IFN alpha-2b therapy, they persisted for up to 6 months after cessation of treatment. They concluded that the use of IFN alpha-2b could be considered as a potential short-term therapeutic strategy [25]. In another comparative study, 2 immunomodulatory agents, tacrolimus and IFN-∝2b compared in the treatment of VKC that had an equal effect in that's therapeutic effects [11] that were similar to our case study.…”

Section: Discussionsupporting

confidence: 72%

Is there an alternative therapy for refractory vernal keratoconjunctivitis? ‎

Akbari¹

2022

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 72%

Is there an alternative therapy for refractory vernal keratoconjunctivitis? ‎

Akbari¹

2022

J Adv Pharm Educ Res

View full text Add to dashboard Cite

show abstract

“…Therefore, non-steroidal medications are desirable for the treatment of VKC as alternative, but new topical agents with dual antiallergic activity (mast cell stabilizers and antihistamine) may also be used for long-term treatment of allergic inflammation to alleviate signs and symptoms of the disease [21,25,26]. A recent study has reported that topical interferon alpha 2b treatment seems to offer a safe and effective alternative for the treatment of refractory vernal keratoconjunctivitis for a brief period [27].…”

Section: Discussionmentioning

confidence: 99%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

“…Patients with giant papillae associated with corneal shield ulcer may benefit from resection of papillae and autologous conjunctival or allogeneic amniotic membrane graft. [10][11][12][13][14][15][16][17][18][19] Our study revealed good response with oral DEC as an adjuvant therapy in refractory VKC associated with eosinophilia. There was no exacerbation of the disease in 91.66% of patients within 6 months.…”

Section: Resultsmentioning

confidence: 93%

Oral Diethylcarbamazine as Adjuvant Therapy in Refractory Vernal Keratoconjunctivitis - A Prospective Study

Kamishetty¹,

Shashikala²

2015

jebmh

View full text Add to dashboard Cite

To evaluate the role of oral diethylcarbamazine as an adjuvant therapy in refractory vernal keratoconjunctivitis associated with eosinophilia. MATERIALS AND METHODS: Twenty four patients with bilateral refractory severe vernal keratoconjunctivitis (VKC) and eosinophilia were included in the prospective study. The average age of patients was 8.25 years (range 3 to 14 years) including 18 males (75%) and 6 females (25%). The absolute eosinophil count (AEC) in these patients was on an average 1065.79 cells/µL (range 530 to 3120 cells/µL). All the patients were given oral diethylcarbamazine (DEC) as an adjuvant therapy for refractory VKC. RESULTS: At an average follow up of 7.2 months (range 6 to 11 months), only 2 cases (8.3%) had recurrent exacerbation of VKC. Signs and symptoms of VKC improved significantly with remission in all the patients within 3 months. Absolute eosinophil count repeated after 3 months of starting DEC was on an average 376.25 cells/µL (range 200 to 950 cells/µL). There was a statistically significant reduction in eosinophilia following oral DEC at p<0.0001. CONCLUSION: Oral DEC effectively reduces eosinophilia seen in refractory VKC. It is a cost effective and safe alternative as an adjuvant in refractory VKC with good clinical response.

show abstract

The Efficacy of Topical Interferon Alpha 2b Treatment in Refractory Vernal Keratoconjunctivitis

Cited by 12 publications

References 29 publications

Is there an alternative therapy for refractory vernal keratoconjunctivitis? ‎

Is there an alternative therapy for refractory vernal keratoconjunctivitis? ‎

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Oral Diethylcarbamazine as Adjuvant Therapy in Refractory Vernal Keratoconjunctivitis - A Prospective Study

Contact Info

Product

Resources

About